Clinical trials: SARS-CoV-2
Multiple Myeloma
COVID19 OutcomeS in Myeloma and the Impact of VaCcines
The COVID-19 pandemic has had an outsized impact on individuals with underlying social and medical vulnerability, leading to increased rates of severe disease, hospitalization, and death in these groups.
- Trial name
- COSMIC (NCT05831787)
- Testing
- Patient Reported Outcomes
- Where
- 2 sites in United States
- Volunteers
- 201 people
- Sponsor
- ASH Research Collaborative
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-COV-2) vaccine in adults 18 years of age or older.
- Trial name
- NCT04405076
- Testing
- Biological: mRNA-1273, mRNA-1273.351
- Where
- 8 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.
- Trial name
- NCT04343755
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Hackensack Meridian Health
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
Diabetes Mellitus, Covid19
CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))
The purpose of this research is to determine if CGM (continuous glucose monitors) used in the hospital in patients with COVID-19 and diabetes treated with insulin will be as accurate as point of care (POC) glucose monitors.
- Trial name
- NCT04756141
- Testing
- Continuous Glucose Monitor (CGM)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
COVID-19
COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)
Background: People who are recovering from COVID-19 may continue to have problems that affect their daily life. For instance, they might feel overly tired.
- Trial name
- NCT04595773
- Testing
- Aerobic Exercise Training, Education
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
COVID-19
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
A multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis
- Trial name
- NCT04498273
- Testing
- Apixaban 2.5 MG, Apixaban 5MG, Aspirin
- Where
- 71 sites in United States
- Volunteers
- 657 people
- Sponsor
- Frank C Sciurba
COVID-19 (Coronavirus Disease 2019), Hypoxia
Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)
An open-label, randomised, Best-Available-Care (BAC) and historic-controlled trial of nebulised dornase alfa [2.5 mg BID (bis in die)] for 7 days in participants with COVID-19 who are admitted to hospital and are at risk of…
- Trial name
- COVASE (NCT04359654)
- Testing
- Dornase Alfa Inhalation Solution [Pulmozyme]
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- University College, London
COVID-19
VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of VIR-7831 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780281
- Testing
- VIR-7831, Remdesivir
- Where
- 105 sites in United States, Denmark and 6 more
- Volunteers
- 367 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of…
- Trial name
- RSVictory (NCT05330975)
- Testing
- mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Where
- 62 sites in United States
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19 Infection
CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5 days of treatment of participants with positive COVID-19 and at least one symptom of COVI019 in an out-patient setting.
- Trial name
- CRISIS2 (NCT04575038)
- Testing
- Brequinar
- Where
- 14 sites in United States
- Volunteers
- 115 people
- Sponsor
- Clear Creek Bio, Inc.
COVID, Sars-CoV2
Novel Agents for Treatment of High-risk COVID-19 Positive Patients
This is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals.
- Trial name
- NCT04374019
- Testing
- Ivermectin, Camostat Mesilate, Artemesia annua
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Susanne Arnold
Coronavirus, Covid19
ACTIV-2: A Study for Outpatients With COVID-19
Drug studies often look at the effect one or two drugs have on a medical condition, and involve one company. There is currently an urgent need for one study to efficiently test multiple drugs from more than one company, in people…
- Trial name
- NCT04518410
- Testing
- bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV)
- Where
- 252 sites in United States, Argentina and 7 more
- Volunteers
- 4,044 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection.
- Trial name
- NCT05047601
- Testing
- PF-07321332, Ritonavir
- Where
- 170 sites in United States, Argentina and 15 more
- Volunteers
- 2,954 people
- Sponsor
- Pfizer
COVID-19, COVID
Pegylated Interferon Lambda Treatment for COVID-19
Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs.placebo in up to 20 subjects with COVID-19 infection.
- Trial name
- NCT04343976
- Testing
- Pegylated interferon lambda
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Raymond Chung
SARS-CoV-2 Infection
Plasma Therapy of COVID-19 in Severely Ill Patients
This randomized blinded multi-center phase 2 trial will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma among adults with severe COVID-19. Adults ≥18 years of age may participate.
- Trial name
- NCT04359810
- Testing
- Convalescent Plasma (anti-SARS-CoV-2 plasma), Non-convalescent Plasma (control plasma)
- Where
- 4 sites in United States, Brazil
- Volunteers
- 223 people
- Sponsor
- Max O'Donnell
SARS-CoV2 Infection, COVID-19
BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19)
This is a study of the BinaxNOW Covid-19 Ag Card as a method to rapidly identify SARS-CoV-2 infection in asymptomatic children, teachers, and other school staff for exclusion.
- Trial name
- NCT05087524
- Testing
- BinaxNOW Ag Card
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
COVID 19 Associated Coagulopathy
Covid-19 Associated Coagulopathy
This prospective, randomized, open-label, multi-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who…
- Trial name
- NCT04360824
- Testing
- Intermediate dose thromboprophylaxis, Standard of Care thromboprophylaxis
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- University of Iowa
SARS-CoV-2 Infection
Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19
The purpose of this study is to compare the risks of COVID-19 in individuals from Chicagoland communities randomized to low (400 IU/day) vs. moderate (4,000 IU/day) or high (10,000 IU/day) dose vitamin D.
- Trial name
- NCT04868903
- Testing
- Vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 1,475 people, healthy volunteers welcome
- Sponsor
- University of Chicago